CCAM
MIST icon

Cascades Capital Asset Management’s Milestone Pharmaceuticals MIST Stock Holding History

Cascades Capital Asset Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
+83,610
New +$134K 0.04% 155
2026
Q1 		– Sell
-77,510
Closed -$157K – 171
2025
Q4 		$157K Buy
77,510
+175
+0.2% +$377 0.07% 134
2025
Q3 		$155K Buy
77,335
+10,200
+15% +$17.9K 0.07% 132
2025
Q2 		$130K Buy
+67,135
New +$89.5K 0.07% 131

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Cascades Capital Asset Management's MIST Position: Q2 2026 in Review

Cascades Capital Asset Management opened a new position in Milestone Pharmaceuticals (MIST) in Q2 2026: 83,610 shares worth $112K. The stake represents 0.04% of the portfolio and ranks #155 among its holdings. This is a return to the name: Cascades Capital Asset Management previously reported a position in MIST as recently as Q4 2025.

Cascades Capital Asset Management first reported a position in MIST in Q2 2025 and has held it in 4 quarters since. The position peaked at $157K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Cascades Capital Asset Management held 83,610 shares of Milestone Pharmaceuticals worth $112K as of Q2 2026.
  • Milestone Pharmaceuticals was a new Cascades Capital Asset Management position in Q2 2026.
  • Milestone Pharmaceuticals made up 0.04% of Cascades Capital Asset Management's portfolio in Q2 2026, its #155 holding.
  • Cascades Capital Asset Management first reported a position in Milestone Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Cascades Capital Asset Management's Milestone Pharmaceuticals position peaked at $157K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Cascades Capital Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.